Published online Jun 28, 2026. doi: 10.3748/wjg.116003
Revised: February 5, 2026
Accepted: March 23, 2026
Published online: June 28, 2026
Processing time: 150 Days and 1.9 Hours
Transcatheter arterial chemoembolization (TACE) is a primary interventional modality for intermediate-to-advanced hepatocellular carcinoma (HCC). How
To establish a predictive model for postoperative complications in patients with HCC undergoing TACE.
A retrospective analysis was conducted on 386 patients with HCC who underwent interventional therapy at our hospital from January 2023 to December 2024. Patients were divided into a complication group (n = 104) and a control group (n = 282) based on postoperative complication occurrence. General clinical data and nursing-related indicators were collected and compared between groups. Multivariate logistic regression analysis was used to identify independent risk factors, construct a risk prediction model, and validate its discriminatory power and calibration by using receiver operating characteristic curve and Hos
The incidence of complications following interventional therapy for HCC in this study was 26.94%. Factors associated with complications included age ≥ 60 years, liver cirrhosis, vascular invasion, procedure duration ≥ 2 hours, TACE sessions > 2, Child-Pugh grade B, tumor diameter ≥ 5 cm, nutritional risk (Nutritional Risk Screening 2002 ≥ 3), anxiety (Self-Rating Anxiety Scale ≥ 50), depression (Self-Rating Depression Scale ≥ 53), caregiver burden (high Zarit Burden Interview Score), functional independence (low Exercise of Self-Care Agency Scale Score), quality of life (low Quality of Life Instruments for Cancer Patients - General Module Score), and low compliance with early postoperative activity and exercise were all independent risk factors (P < 0.05). The predictive model demonstrated a C-index of 0.773, an area under the curve of 0.936, sensitivity of 93.25%, specificity of 84.96%, and good calibration (Hosmer-Lemeshow test, P = 0.382).
The TACE postoperative complication prediction model derived during the research combines multidimensional clinical and nursing predictors, which proves a high predictive quality and clinical usefulness. It provides healthcare professionals with a scientifically grounded assessment tool to facilitate risk stratification management and precision nursing.
Core Tip: This study developed and validated a multidimensional integrated model for predicting the risk of complications following transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. By innovatively incorporating clinical characteristics and procedural parameters with nursing-specific indicators including psychological status, nutrition, and self-care capacity, the model achieved high predictive accuracy (area under the curve = 0.936). The model offers nurses a logical and user-friendly decision-support model that helps them to predict complications early and accurately distribute nursing resources.
- Citation: Wang H, Guo HT, Shen J, Zhang F, Jiang YJ, Liu ZX. Assessment of the value of complication risk prediction models following interventional therapy for hepatocellular carcinoma in nursing decision-making. World J Gastroenterol 2026; 32(24): 116003
- URL: https://www.wjgnet.com/1007-9327/full/v32/i24/116003.htm
- DOI: https://dx.doi.org/10.3748/wjg.116003
Hepatocellular carcinoma (HCC) is a high incidence and mortality malignant tumor worldwide[1]. One of the most effective treatments in the management of the progressive stages of HCC is transcatheter arterial chemoembolization (TACE) which is effective in controlling tumor progression though accompanied by high rates of postoperative complications that largely influence patient prognosis[2-4]. Today, nursing interventions are mostly based on experience and standard guidelines, without risk prediction tools of integrated multifactorial analysis, which is an obstacle to precision nursing management implementation[5,6]. Thus, it is important to create a model of complication risks prediction that incorporates both clinical features and nursing-related factors, ensuring that the nursing decision-making in TACE patients can be early-warned and supported. The purpose of this study was to combine the multidimensional risk factors using logistic regression to develop and test a model of risk prediction of postoperative complications using TACE. The aim of this approach is to equip nursing staff with a scientific and practical risk assessment instrument, to streamline the allocation of the nursing resources, and to improve the nursing quality and patient outcomes.
In this research, 386 cases of HCC were participants, and the cases were chosen January 2023-December 2024. Patients were divided into a complication group (n = 104) and a control group (no complications, n = 282) based on whether complications occurred after interventional therapy. Detailed characteristics of both groups were presented in Table 1. Comparisons of clinical data including gender, body mass index (BMI), underlying medical conditions (hypertension, diabetes, hyperlipidemia), and history of alcohol consumption and smoking revealed no statistically significant differences (P > 0.05). This study was approved by the institutional ethics committee. Complications following interventional therapy included upper abdominal pain, fever, nausea and vomiting, intra-abdominal hemorrhage, intra-abdominal infection, liver abscess, and tachycardia.
| Complication types | n | Percentage (%) |
| Nausea and vomiting | 42 | 40.38 |
| Upper abdominal pain | 12 | 11.54 |
| Fever | 29 | 27.88 |
| Liver abscess | 6 | 5.77 |
| Intra-abdominal hemorrhage | 3 | 2.88 |
| Tachycardia | 3 | 2.88 |
| Intra-abdominal infection | 9 | 8.65 |
This retrospective cohort study enrolled patients who underwent their first TACE treatment between January 2023 and December 2024. The follow-up concluded on June 30, 2025, ensuring a minimum follow-up duration of six months for all participants. Complications defined in this study included both early (≤ 30 days) and delayed (> 30 days) post-procedural events, such as liver abscess, intra-abdominal infection, hemorrhage, and hepatic failure. Data were comprehensively collected and verified through outpatient reviews, readmission records, or telephonic follow-ups.
Inclusion criteria: Patients were eligible for inclusion if they: (1) Met the diagnostic criteria for primary HCC[7], as confirmed by clinical presentation, imaging (computed tomography/magnetic resonance imaging), and pathological examination; (2) Fulfilled the indications for interventional therapy according to the NCCN Clinical Practice Guidelines in Oncology[8] and elected to undergo the procedure; (3) Possessed complete clinical records and had no contraindications for interventional maneuvers; and (4) Provided informed consent from both the patients and their legal guardians for study participation.
Exclusion criteria: (1) Presence of severe systemic comorbidities such as major cardiovascular or cerebrovascular disease, severe neurological disorders, or respiratory failure; (2) Receipt of immunosuppressive agents, glucocorticoids, anti
The electronic medical record system of the hospital was searched to extract clinical data on a retrospective basis. The period of follow-up was over on June 30, 2025, with all patients having at least six months of observation. Complications were considered as any procedure related negative events that occurred since the commencement of TACE to the follow up. These events were classified as early [i.e., symptoms of post-embolization syndrome (pain, pyrexia, emesis, etc.)] and delayed (i.e., liver abscess, abdominal infection and bleeding). All complications were adjudicated based on clinical diagnosis or confirmed via objective imaging findings.
Data collection and cross-verification were independently performed by two uniformly trained researchers, covering the following dimensions.
General information: (1) Demographic characteristics (gender, age, BMI); (2) History of underlying diseases (diabetes, hypertension, hyperlipidemia, and cirrhosis, etc.); (3) Lifestyle habits [smoking history (defined as ≥ 1 cigarette per day for ≥ 6 months), alcohol consumption history (defined as ≥ 1 episode per week with single intake > 30 mL, sustained for ≥ 6 months)]; and (4) TACE procedure parameters (vascular invasion status, maximum tumor diameter, number of tumors, preoperative Child-Pugh grade, number of TACE treatments, lymph node metastasis status).
The nursing-related indicators and assessment methods: (1) Self-care ability at 72 hours post-surgery: Assessed using the Exercise of Self-Care Agency Scale (ESCA). This 43-item scale covers four dimensions: Sense of responsibility for self-care, self-care skills, health knowledge level, and self-concept. The total score ranges from 0 point to 172 points, with higher scores indicating stronger self-care ability. Assessment occurs within 72 hours post-surgery; (2) Quality of life assessment: Evaluated using the Quality-of-Life Instruments for Cancer Patients - General Module (QLICP-LI) with liver cancer-specific items. This scale consists of 30 questions, which assess four domains: Physical functioning, psychological functioning, social functioning and symptoms/side effects. The total scores will be between 0 and 100, with a high score being a sign of a better quality of life. Time of assessment: 1 week after surgery; (3) Primary caregiver burden assessment: Zarit Burden Interview (ZBI). This is a 22-item scale that encompasses the personal burden, emotional burden, and social burden. The total scores are 0-88, above 40 indicates high burden. Primary caregivers completed the assessment within 72 hours postoperatively; (4) Psychological state assessment: Evaluated using the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS). The positive anxiety and depression states, respectively, are a total score 50 or above on SAS and 53 or above on SDS. Time of assessment: 24 hours before surgery; (5) Nutritional Risk Screening (NRS): Evaluated with the NRS 2002 scale. A total score ≥ 3 indicates nutritional risk. Evaluation during 24 hours preoperative; and (6) Postoperative early mobility and functional exercise adherence: Document patient adherence to bedside mobility and functional exercises during 24-72 hours after surgery. Good compliance was defined as 80% of the prescribed volume and poor compliance as below 80% of the prescribed volume.
This study involved continuous variables, which were tested and observed to have a normal distribution. Independent samples t-tests were used to analyze quantitative data and 2-sample tests were used to analyze categorical data with the help of SPSS 24.0 software. The independent risk factors in complications after HCC interventional therapy were determined using multivariate logistic regression analysis and a risk prediction model was developed using the regression coefficients. The rms package of the R 3.6.1 software was used to model visualization. Calibration of the model was done through the Hosmer-Lemeshow test and calibration curves, and the calibration performance was measured through the calculation of the area under the curve (AUC) using the receiver operating characteristic curve. The significance threshold was set at P < 0.05.
This study included 386 patients undergoing interventional therapy for HCC, among whom 104 developed complications, yielding an incidence rate of 26.94% (Table 1). The complication group and control group showed statistically significant differences in age, cirrhosis, vascular invasion, operative time, number of TACE procedures, Child-Pugh classification, tumor diameter, and all nursing-related indicators (including NRS 2002 Score, SAS Score, SDS Score, ZBI Score, QLICP-LI Score, and compliance with early postoperative activity and functional exercise) (P < 0.05). No statistically significant differences were observed between the two groups in terms of gender, BMI, history of underlying diseases (hypertension, diabetes, hyperlipidemia), smoking history, drinking history, number of tumors, or lymph node metastasis (P > 0.05), as shown in Table 2.
| Items | Complication group (n = 104) | Control group (n = 282) | t/χ2 | P value |
| Gender | 0.166 | 0.684 | ||
| Male | 54 (51.92) | 153 (54.26) | ||
| Female | 50 (48.08) | 129 (45.74) | ||
| Age (years) | 16.100 | < 0.001 | ||
| ≥ 60 | 74 (71.15) | 136 (48.23) | ||
| < 60 | 30 (28.85) | 146 (51.77) | ||
| Body mass index (kg/m2) | 2.436 | 0.119 | ||
| ≥ 23.9 | 71 (68.27) | 168 (59.57) | ||
| < 23.9 | 33 (31.73) | 114 (40.43) | ||
| Hypertension | 1.314 | 0.252 | ||
| Yes | 23 (22.12) | 48 (17.02) | ||
| No | 81 (77.88) | 234 (82.98) | ||
| Diabetes | 0.033 | 0.855 | ||
| Yes | 42 (40.38) | 111 (39.36) | ||
| No | 62 (59.62) | 171 (60.64) | ||
| Hyperlipidemia | 1.097 | 0.295 | ||
| Yes | 25 (24.04) | 83 (29.43) | ||
| No | 79 (75.96) | 199 (70.57) | ||
| Liver cirrhosis | 37.083 | < 0.001 | ||
| Yes | 78 (75.00) | 113 (40.07) | ||
| No | 26 (25.00) | 169 (59.93) | ||
| Smoking history | 0.548 | 0.459 | ||
| Yes | 40 (38.46) | 97 (34.40) | ||
| No | 64 (61.54) | 185 (65.60) | ||
| Alcohol consumption history | 0.352 | 0.553 | ||
| Yes | 35 (33.65) | 86 (30.50) | ||
| No | 69 (66.35) | 196 (69.50) | ||
| Tumor diameter (cm) | 24.961 | < 0.001 | ||
| ≥ 5 | 66 (63.46) | 99 (35.11) | ||
| < 5 | 38 (36.54) | 183 (64.89) | ||
| Number of tumors | 0.275 | 0.600 | ||
| Single discharge | 43 (41.35) | 125 (44.33) | ||
| Multiple discharges | 61 (58.65) | 157 (55.67) | ||
| Vascular invasion | 35.225 | < 0.001 | ||
| Yes | 80 (76.92) | 121 (42.91) | ||
| No | 24 (23.08) | 161 (57.09) | ||
| Operative duration (hours) | 14.712 | < 0.001 | ||
| ≥ 2 | 57 (54.81) | 94 (33.33) | ||
| < 2 | 47 (45.19) | 188 (66.67) | ||
| Lymph node metastasis | 1.975 | 0.160 | ||
| Yes | 59 (56.73) | 182 (64.54) | ||
| No | 45 (43.27) | 100 (35.46) | ||
| Child-Pugh grade | 15.524 | < 0.001 | ||
| Grade A | 57 (54.81) | 213 (75.53) | ||
| Grade B | 47 (45.19) | 69 (24.47) | ||
| Transcatheter arterial chemoembolization procedures (times) | 14.243 | < 0.001 | ||
| > 2 | 85 (81.73) | 173 (61.35) | ||
| ≤ 2 | 19 (18.27) | 109 (38.65) | ||
| Preoperative Nutritional Risk Screening 2002 Score | 6.919 | 0.009 | ||
| ≥ 3 | 68 (65.38) | 142 (50.35) | ||
| < 3 | 36 (34.62) | 140 (49.65) | ||
| Postoperative Exercise of Self-Care Agency Scale Score | 87.32 ± 12.15 | 102.46 ± 10.83 | 11.784 | < 0.001 |
| Postoperative Quality of Life Instruments for Cancer Patients - General Module Score | 52.17 ± 8.26 | 68.43 ± 7.95 | 17.641 | < 0.001 |
| Self-Rating Anxiety Scale Score | 11.026 | 0.001 | ||
| ≥ 50 | 49 (47.12) | 82 (29.08) | ||
| < 50 | 55 (52.88) | 200 (70.92) | ||
| Self-Rating Depression Scale Score | 10.486 | 0.001 | ||
| ≥ 53 | 51 (49.04) | 88 (31.21) | ||
| < 53 | 53 (50.96) | 194 (68.79) | ||
| Zarit Burden Interview Score | 45.63 ± 9.27 | 32.15 ± 8.46 | 13.530 | < 0.001 |
| Early postoperative ambulation (%) | 25.165 | < 0.001 | ||
| ≥ 80 | 28 (26.92) | 157 (55.67) | ||
| < 80 | 76 (73.08) | 125 (44.33) | ||
| Functional exercise completion rate (%) | 24.741 | < 0.001 | ||
| ≥ 80 | 22 (21.15) | 139 (49.29) | ||
| < 80 | 82 (78.85) | 143 (50.71) |
Using complications after interventional treatment for HCC as the dependent variable (yes = 1, no = 0), statistically significant factors from Table 2 (e.g., age, tumor diameter, operative duration, TACE procedures) were incorporated as independent variables into a logistic regression model. Results indicated that age, liver cirrhosis, vascular invasion, operative duration, tumor diameter, TACE procedures, Child-Pugh B grade, preoperative NRS 2002 Score, postoperative ESCA Score, QLICP-LI Score, SAS Score, SDS Score, ZBI Score, early postoperative ambulation compliance, and functional exercise completion rate were all independent risk factors for complications following interventional therapy for HCC (P < 0.05), as shown in Tables 3 and 4.
| Related factors | Variable names | Variable assignment |
| Age | X1 | ≥ 60 years = 1, < 60 years = 0 |
| Liver cirrhosis | X2 | Yes = 1, no = 0 |
| Tumor diameter | X3 | ≥ 5 cm = 1, < 5 cm = 0 |
| Vascular invasion | X4 | Yes = 1, no = 0 |
| Operative duration | X5 | ≥ 2 hours = 1, < 2 hours =0 |
| Child-Pugh grade | X6 | Grade B = 1, grade A = 0 |
| Transcatheter arterial chemoembolization Procedures | X7 | > 2 times = 1, ≤ 2 times = 0 |
| Preoperative Nutritional Risk Screening 2002 Score | X8 | ≥ 3 scores = 1, < 3 scores = 0 |
| Postoperative Exercise of Self-Care Agency Scale Score | X9 | Actual value |
| Postoperative Quality of Life Instruments for Cancer Patients-General Module Score | X10 | Actual value |
| Self-Rating Anxiety Scale Score | X11 | ≥ 50 scores = 1, < 50 scores = 0 |
| Self-Rating Depression Scale Score | X12 | ≥ 53 scores = 1, < 53 scores = 0 |
| Zarit Burden Interview Score | X13 | Actual value |
| Early postoperative ambulation compliance | X14 | < 80% = 1, ≥ 80% = 0 |
| Functional exercise completion rate | X15 | < 80% = 1, ≥ 80% = 0 |
| Variable names | Β | SE | χ2 | P value | Odds ratio (95%CI) |
| Constant | -2.867 | 0.218 | - | - | - |
| Age | 0.325 | 0.134 | 5.882 | 0.015 | 1.384 (1.064-1.800) |
| Liver cirrhosis | 0.481 | 0.211 | 5.197 | 0.023 | 1.618 (1.070-2.446) |
| Tumor diameter | 0.296 | 0.108 | 7.512 | 0.006 | 1.344 (1.088-1.661) |
| Vascular invasion | 1.114 | 0.369 | 9.114 | 0.003 | 3.047 (1.478-6.279) |
| Operative duration | 0.563 | 0.271 | 4.316 | 0.038 | 1.756 (1.032-2.987) |
| Child-Pugh grade | 0.601 | 0.254 | 5.599 | 0.018 | 1.824 (1.109-3.001) |
| Transcatheter arterial chemoembolization Procedures | 0.742 | 0.302 | 6.037 | 0.014 | 2.100 (1.162-3.796) |
| Preoperative Nutritional Risk Screening 2002 Score | 0.309 | 0.114 | 7.347 | 0.007 | 1.362 (1.089-1.703) |
| Postoperative Exercise of Self-Care Agency Scale Score | 0.517 | 0.153 | 11.418 | 0.001 | 1.677 (1.242-2.263) |
| Postoperative Quality of Life Instruments for Cancer Patients - General Module Score | 0.448 | 0.203 | 4.870 | 0.027 | 1.565 (1.051-2.330) |
| Self-Rating Anxiety Scale Score | 0.635 | 0.247 | 6.609 | 0.010 | 1.887 (1.163-3.062) |
| Self-Rating Depression Scale Score | 0.557 | 0.263 | 4.485 | 0.034 | 1.745 (1.042-2.923) |
| Zarit Burden Interview Score | 0.751 | 0.165 | 20.716 | < 0.001 | 2.119 (1.534-2.928) |
| Early postoperative ambulation compliance | 0.495 | 0.223 | 4.927 | 0.026 | 1.640 (1.060-2.540) |
| Functional exercise completion rate | 1.011 | 0.113 | 80.047 | < 0.001 | 2.748 (2.202-3.430) |
This study employed a logistic regression method to construct a predictive model for postoperative complications following HCC intervention. The regression model expression was: Logit(P) = -2.867 + 0.325 × age + 0.481 × liver cirrhosis + 0.296 × tumor diameter + 1.114 × vascular invasion + 0.563 × operative duration + 0.601 × Child-Pugh grade + 0.742 × TACE procedures + 0.309 × preoperative NRS 2002 Score + 0.517 × postoperative ESCA Score + 0.448 × postoperative QLICP-LI Score + 0.635 × SAS Score + 0.557 × SDS Score + 0.751 × ZBI Score + 0.495 × early postoperative ambulation compliance + 1.011 × functional exercise completion rate. After validation, this predictive model demonstrated excellent clinical discriminatory ability with a consistency index of 0.773 (95% confidence interval: 0.746-0.853), indicating reliable predictive efficacy.
The diagnostic value of the risk prediction model was assessed using receiver operating characteristic curve analysis. Results showed that the model achieved an AUC of 0.936 (0.884-0.988), with sensitivity and specificity of 93.25% and 84.96%, respectively (Figure 1). The Hosmer-Lemeshow test and calibration curves were used to evaluate the model calibration. The χ2 statistic was χ2 = 7.354 (P = 0.382), indicating good model calibration. The calibration curve had high fit with the ideal curve, which further confirms the predictive power of the model. Moreover, the analysis of decision curves revealed that the predictive model developed in this study has higher net benefit than other traditional prediction models in a wide range of threshold probabilities, as Figure 2 reveals.
Research has shown[10-12] that more than 80% of patients with HCC miss the chance of a curative operation because of tumor involvement of both lobes of the liver, anatomy, excessive size of the tumor or secondary extrahepatic metastasis. In unresectable or recurrent cases of the disease, TACE is an important palliative treatment option. TACE is a simu
In this study logistic regression analysis showed that clinical and procedural factors like age 60 years and older, liver cirrhosis, vascular invasion, tumor diameter more than 5 cm, Child-Pugh grade B, TACE procedures more than 2 times, and operative duration more than 2 hours were found to be significant risk factors of postoperative complications which was also consistent with other studies[16-18]. This puts an emphasis on the specific improvement in nursing care: (1) Enhance preoperative functional evaluation and postoperative monitoring of vital signs and systemic functions in elderly patients and patients with liver cirrhosis; (2) Strengthen preoperative imaging assessment awareness, coordination between hemodynamic management in the operating room, and enforced strict bed rest and the use of abdominal belts in patients with vascular invasion or large tumors; (3) Increase awareness of cumulative injury risks in patients with case management, schedule optimization of intervention and rest between interventions; and (4) Intensive management of drug metabolism and hydration therapy in Child-Pugh B-grade patients.
Nutritional status [preoperative NRS 2002 Score ≥ 3, odds ratio (OR) = 1.362] is an independent risk factor of postoperative complications among the indicators related to nursing. Malnutrition may lead to weakening of immunity, delay in the healing of tissues, and risk of infections[19]. It is suggested that NRS should be a part of regular nursing examination. In patients at high risk, tailored nutritional care (e.g., adjustment of the diet, enteral/parenteral nutrition) must be implemented early, and the nutritional parameters must be dynamically monitored to achieve proper preoperative nutritional status, which helps to protect the postoperative recovery. The risk of complications is significantly increased by self-care capacity and quality of life (low postoperative ESCA Score, OR = 1.677; low QLICP-LI Score, OR = 1.565). Self-management efficacy and health perception of patients are critical towards postoperative recovery. Systematic health education (e.g., postoperative self-management, medication guidance) should be practiced in nursing to promote patient engagement and compliance. Psychological status (preoperative SAS ≥ 50, OR = 1.887; SDS ≥ 53, OR = 1.745) are also a significant risk factor. Negative emotions can affect adherence and inhibit immunity, slow down recovery.
Preoperative psychological screening of the nursing practice should be performed regularly. In patients with anxiety or depression, liaise with psychiatric units to carry out personalized approaches to such problems, including cognitive behavioral therapy and relaxation training, which may be supported by prescription of medications as needed to help create a favorable psychological climate. The impact family support has on the quality of recovery is immense as caregiver burden (high postoperative ZBI Score, OR = 2.119) is a significant predictor of complications. High burden of caregivers undermines patient compliance and quality of nursing care. Educational guidance, social resource connection, and emotional support should be offered to caregivers by nursing to evaluate the stress of caregiving early postoperatively in order to maximize the capacity of caregiving and improve the family support system. Also, the lack of adherence to early postoperative activities and functional exercises (compliance < 80, OR = 1.640; exercise completion < 80, OR = 2.748) is a significant risk factor that puts people at risk of complications. Any prolonged bed rest and activity restriction may precipitate thrombosis, infection and other complications[20].
These results imply that nursing evaluations cannot be limited to the conventional clinical indicators. They are, instead, advised to combine multidimensional aspects including psychological health, nutritional health, family support and rehabilitation behaviors to develop a systemized and personalized risk evaluation system. In patients with anxiety or depression, psychological intervention needs to be incorporated in the early stages of their care and treatment to improve the adherence to the treatment and the immune functioning. In families with high care giving loads, nursing professionals are advised to take the initiative to provide skills training, emotional support, and links to social support to reduce care stress, thus indirectly enhancing patient recovery outcomes.
The risk prediction model developed in the current study based on the independent risk factors mentioned above showed a predictive performance AUC of 0.936 of post-interventional complications through receiver operating characteristic curve analysis with sensitivity and specificity of 93.25% and 84.96, respectively. This shows that the model has a strong discriminative power and high validity that will give nursing personnel a valid instrument to use to stratify risks of complication. This model has many benefits compared to the traditional single clinical indicators or empirical judgments. One, it had a higher C-index of 0.773 (95% confidence interval: 0.746-0.853) and AUC of 0.936 and thus a better predictor of high-risk patients than most of its equivalents. To the patients who are defined high-risk according to the model, the nursing teams can take the initiative of improving the preoperative preparations, maximizing the intraoperative monitoring guidelines, improving the postoperative monitoring rates, and developing specific contingency measures. Also, the model addresses the constraint of the past studies that only dealt with non-dynamic parameters of the procedures, including operational time and TACE operations. This renders risk assessment closer to the demands of clinical nursing practice which are dynamic. But the cases in this study were all obtained at one center, which is a source of possible selection bias. Past research has largely concentrated on clinical risk factors of postoperative complications after TACE (such as liver function status and tumor characteristics), or have studied their effects on prognosis only based on individual nursing aspects, such as nutrition or psychology.
Three main features of the study contribute to its innovation: (1) Integration: This is the first study that includes clinical (vascular invasion, Child-Pugh classification) and treatment (procedure duration, TACE sessions) and multiple nursing (psychological status, nutritional status, self-care ability, family burden, and rehabilitation behavior) factors into a predictive model, which systematically reflects the multifactorial interactive processes that occur in the development of complications; (2) Practicality: The model has a high predictive efficiency (AUC = 0.936) and a good calibration. All the indicators included are easily accessible in clinical nursing practice, which guarantees high translational applicability; and (3) Early warning value: The model emphasizes the independent predictive value of nursing factors that can be controlled (e.g., early compliance with activities, the rate of functional exercise completion), which can give a clear idea of the time and focus of nursing interventions. This is in response to the shortcomings of the past models which focused too much on biological indicators which are not modifiable.
Overall, the risk prediction model created in the given study is a useful tool that allows the nursing staff to determine the risk of complications after interventional therapy of liver cancer and introduce the concept of tiered nursing care. It is suggested that this model should be combined with dynamic monitoring of the liver work of patients in the clinical nursing practice and be included in the preoperative nursing examination system. By combining liver function monitoring with nursing assessment scales, a comprehensive “prediction-early warning-intervention” nursing management pathway can be established. This approach facilitates the early identification of high-risk patients, optimizes the allocation of nursing resources, enhances nursing quality, and improves patients’ quality of life.
| 1. | Guo Q, Zhu X, Beeraka NM, Zhao R, Li S, Li F, Mahesh PA, Nikolenko VN, Fan R, Liu J. Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data. Sci Rep. 2024;14:28131. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 26] [Reference Citation Analysis (0)] |
| 2. | Chen Y, Zhang J, Hu W, Li X, Sun K, Shen Y, Zhang M, Wu J, Gao S, Yu J, Que R, Zhang Y, Yang F, Xia W, Zhang A, Tang X, Bai X, Liang T. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study. Signal Transduct Target Ther. 2024;9:280. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 4] [Cited by in RCA: 31] [Article Influence: 15.5] [Reference Citation Analysis (0)] |
| 3. | Xu L, Chen S, Cao H, Feng Z, Yang C. Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis. Acta Pharm. 2024;74:405-422. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 4. | Qiu Z, Li Q, Yu C. Latrogenic Cerebral Infarction: A Rare but Sever Complication Caused by Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2023;46:1099-1101. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 5. | Hu M, Fan Z, Han Y. Effect of Perioperative Comprehensive Nursing Intervention on Transcatheter Arterial Chemoembolization in Patients with Primary Hepatic Carcinoma. Evid Based Complement Alternat Med. 2022;2022:9000331. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 3] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 6. | Gu J, Liang Y. Clinical Nursing Paths Benefit Patient Outcomes Undergoing Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. Evid Based Complement Alternat Med. 2022;2022:4655293. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 7. | Tan YW. Risk stratification of primary liver cancer. World J Clin Cases. 2022;10:9545-9549. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 8. | Bojanović A, Bosnjaković P, Stojanović M, Marković M, Mrvić M, Radić S, Radovanović Z. [Precision TACE in therapy of primary malignant tumors of liver/hepatocellular carcinoma (HCC)]. Acta Chir Iugosl. 2009;56:143-148. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 4] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
| 9. | Raj A, Pillai G, Divakar A, Shivam V, Nair A. Association of Thyroid Function and Severity of Illness in Liver Cirrhosis as Measured by Child-Pugh Score. Cureus. 2023;15:e36618. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 10. | Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835-1847. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 418] [Cited by in RCA: 376] [Article Influence: 125.3] [Reference Citation Analysis (11)] |
| 11. | Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:559-568. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 220] [Cited by in RCA: 187] [Article Influence: 37.4] [Reference Citation Analysis (3)] |
| 12. | Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, Moreno-Luna L, Roberts LR, Chen VL, Parikh ND. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Med. 2023;12:2590-2599. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 81] [Cited by in RCA: 63] [Article Influence: 21.0] [Reference Citation Analysis (5)] |
| 13. | Yang C, Yang HC, Luo YG, Li FT, Cong TH, Li YJ, Ye F, Li X. Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness. Cardiovasc Intervent Radiol. 2024;47:964-977. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 9] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 14. | Yang W, Qian C, Luo J, Chen C, Feng Y, Dai N, Li X, Xiao H, Yang Y, Li M, Li C, Wang D. Efficacy and Safety of Preoperative Transcatheter Rectal Arterial Chemoembolisation in Patients with Locally Advanced Rectal Cancer: Results from a Prospective, Phase II PCAR Trial. Clin Oncol (R Coll Radiol). 2024;36:233-242. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 15. | Yuan M, Chen TY, Chen XR, Lu YF, Shi J, Zhang WS, Ye C, Tang BZ, Yang ZG. Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study. World J Clin Cases. 2022;10:8535-8546. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 3] [Cited by in RCA: 6] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
| 16. | Lu H, Liang B, Xia X, Zheng C. Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma. BMC Cancer. 2024;24:1085. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 8] [Cited by in RCA: 9] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 17. | Lu Y, Xu MY, Lu L, Gu ZW, Yin AQ, Yin YF. Quality of care combined with mindfulness-based stress reduction intervention in patients undergoing arterial interventional embolization for liver tumors. World J Gastrointest Surg. 2025;17:105826. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (4)] |
| 18. | Yang Y, Dang Z, Lu P, Qian Y, Lin K, Pan Z, Lau WY, Zhou W. Impact of pathological response after preoperative transcatheter arterial chemoembolization (TACE) on incidences of microvascular invasion and early tumor recurrence in hepatocellular carcinoma: a multicenter propensity score matching analysis. Hepatobiliary Surg Nutr. 2022;11:386-399. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 27] [Cited by in RCA: 27] [Article Influence: 6.8] [Reference Citation Analysis (0)] |
| 19. | Zhou J, Chen L, Zhang Z, Wu B. Analysis of risk factors for the increased incidence of gallstone caused by hepatectomy: A retrospective case-control study. Front Surg. 2023;10:1097327. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 20. | Assimakopoulos SF, Bhagani S, Aggeletopoulou I, Tsounis EP, Tsochatzis EA. The role of gut barrier dysfunction in postoperative complications in liver transplantation: pathophysiological and therapeutic considerations. Infection. 2024;52:723-736. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 7] [Cited by in RCA: 13] [Article Influence: 6.5] [Reference Citation Analysis (0)] |